A Phase II Study: Ironotecan and Etoposide as treatment for Refractory, Metastatic Breast Cancer.
Phase of Trial: Phase II
Latest Information Update: 19 Nov 2015
At a glance
- Drugs Etoposide (Primary) ; Irinotecan (Primary)
- Indications Advanced breast cancer
- Focus Therapeutic Use
- 01 Dec 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 23 Mar 2012 Planned end date changed from 1 Dec 2011 to 1 Dec 2012 as reported by ClinicalTrials.gov.
- 19 Oct 2011 Planned end date changed from 1 Feb 2011 to 1 Dec 2011 as reported by ClinicalTrials.gov.